Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2024.1496176 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Dóra Paróczai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, University of Szeged, Szeged, Hungary. Hauptthemen laut MEDLINE: Lopinavir, Ritonavir, Darunavir, Drug Repositioning. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Drug repurposing has become a widely adopted strategy to minimise research time, costs, and associated risks. Combinations of protease inhibitors such as lopinavir and darunavir with ritonavir have been repurposed as treatments for COVID-19. Although lopinavir-ritonavir (LPV/r) and darunavir-ritonavir (DRV/r) have shown in vitro efficacy against COVID-19, the results in human studies have been inconsistent. Therefore, our objective was to compare the efficacy of LPV/r and DRV/r in COVID-19 patients admitted to a tertiary centre in Romania. Research design and methods A clinical dataset from 417 hospitalised patients was analysed. Patients were assigned to the LPV/r, DRV/r, or control (standard-of-care) group based on clinical decisions made by the attending infectious disease specialists, aligned with national treatment protocols. Kaplan-Meier and Cox proportional hazards regression analyses were conducted to compare in-hospital mortality and to identify factors associated with clinical improvement or fatal outcomes.
Results
By day 10, more patients showed improvement with LPV/r and DRV/r (p=0.03 and 0.01, respectively), but only LPV/r was associated with improved survival compared to the control group (p=0.05). Factors associated with mortality included male gender (HR: 3.63, p=0.02), diabetes (HR: 2.49, p=0.03), oxygen saturation below 90% at admission (HR: 5.23, p<0.01), high blood glucose levels (HR: 3.68, p=0.01), age (HR: 1.04, p=0.02), and more than 25% lesion extension on chest CT scan (HR: 2.28, p=0.03).
Conclusions
LPV/r, but not DRV/r, showed a survival benefit in patients hospitalised with COVID-19, but these findings deserve further investigation in a randomised clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology, University of Szeged, Szeged, Hungary.
- Albert Szent-Györgyi Health Center, Pulmonology Clinic, University of Szeged, Deszk, Hungary.
- North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
- Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Manchester, United Kingdom.
- Department of Infectious Diseases, Infectious Diseases and Pulmonology Clinical Hospital, Timisoara, Romania.
- Department of Pulmonology, University of Medicine and Pharmacy Timisoara, Timisoara, Romania.
Zitieren
APA
Paróczai, D., Bikov, A., Blidaru, A., Bobu, E., Lascu, A., Mot, C. I., Mihaicuta, S., & Frent, S. (2025). Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1496176
Vancouver
Paróczai D, Bikov A, Blidaru A, Bobu E, Lascu A, Mot CI, et al. Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2024.1496176
BibTeX
@article{Parczai2025,
author = {Paróczai, Dóra and Bikov, András and Blidaru, Andreea and Bobu, Emanuel and Lascu, Ana and Mot, Cristian Ion and Mihaicuta, Stefan and Frent, Stefan},
title = {Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2024.1496176}
}
EUVIMED